CIP
NVO

Convergence Investment Partners’s Novo Nordisk NVO Stock Holding History

Convergence Investment Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-832
Closed -$20K – 700
2018
Q1 		$20K Buy
+832
New +$21.8K ﹤0.01% 596
2015
Q2 		– Sell
-8,540
Closed -$228K – 399
2015
Q1 		$228K Sell
8,540
-1,208
-12% -$27.8K 0.03% 340
2014
Q4 		$206K Sell
9,748
-194
-2% -$4.33K 0.03% 337
2014
Q3 		$237K Buy
9,942
+1,216
+14% +$28K 0.03% 328
2014
Q2 		$202K Sell
8,726
-4,064
-32% -$89.7K 0.03% 351
2014
Q1 		$292K Sell
12,790
-4,380
-26% -$93.3K 0.04% 305
2013
Q4 		$317K Sell
17,170
-3,290
-16% -$57.3K 0.05% 300
2013
Q3 		$346K Sell
20,460
-5,370
-21% -$90.3K 0.07% 225
2013
Q2 		$400K Buy
+25,830
New +$430K 0.1% 217

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Convergence Investment Partners's NVO Position: Q2 2018 in Review

Convergence Investment Partners sold out of Novo Nordisk (NVO) in Q2 2018, closing a stake of 832 shares — an estimated $20K sold.

Convergence Investment Partners first reported a position in NVO in Q2 2013 and held it in 9 quarters. The position peaked at $400K in Q2 2013. 537 funds tracked by Wall St. Rank hold NVO as of Q2 2018.

  • Convergence Investment Partners reported no remaining Novo Nordisk position as of Q2 2018 after selling out during the quarter.
  • Convergence Investment Partners sold 832 Novo Nordisk shares in Q2 2018, an estimated $20K.
  • Convergence Investment Partners first reported a position in Novo Nordisk in Q2 2013 and held it in 9 quarters.
  • Convergence Investment Partners's Novo Nordisk position peaked at $400K in Q2 2013.
  • 537 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2018.

Based on Convergence Investment Partners's 13F filing for Q2 2018, filed 7 Aug 2018.